Lisata Therapeutics Inc (LSTA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.06-2.75%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · LSTA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -54.9% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
LSTA — litigation filed
Dated 2026-09-17
of this Current Report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2 to this Current Report on Form 8-K, shall not be deemed to be incorporated by reference in the filings of the Company under the Securities Act. Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: stockholder approval of the Parent Stockholder Matter…
Why it matters: The trial tests whether MAR001/005 can lower very high triglyceride levels. The company named this as a key clinical milestone.
Watch forTopline Phase 2b data in Q4 2027 meet the trial's main goal and show lower triglyceride levels.
Also watch forTopline data miss the trial's main goal, show no meaningful triglyceride drop, or slip past Q4 2027.
Why it matters: This study tests whether MAR002 can lower IGF-1 in people with acromegaly. The company named it as a key milestone for 2027.
Watch forQ4 2027 topline data show a clear drop in IGF-1 and meet the trial's main goal.
Also watch forThe trial misses its main goal, shows no clear IGF-1 drop, or reports after Q4 2027.
Why it matters: The company said the money would fund the MAR001/005 and MAR002 trials through key milestones. Cash use and trial progress will test that plan.
Supportive ifCompany updates show the $225 million is funding both trials. No announced cuts or delays affect the planned Q4 2027 data.
Worry ifThe company reports a major trial delay, stops either program, or says funds no longer cover planned goals.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$381 on $10,000 · ±3.8% | How much price usually moves either way. |
| Bad day | $913 loss on $10,000 · 9.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,036 loss on $10,000 · 80.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.